DNA & Genetics Recursion’s Incoming CEO on Turning AI Drugs Into Clinical Proof PointsBy adminDecember 1, 20250 After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan,…
DNA & Genetics uniQure Staggers at FDA, Recursion’s Microglia Map, Leadership TransitionsBy adminNovember 8, 20250 uniQure’s “game changing” data announced in September, which showed significant slowing of Huntington’s disease (HD) progression in patients treated with…
